Profile of Minocycline and Its Potential in the Treatment of Schizophrenia.

Lulu Zhang,Jingping Zhao
DOI: https://doi.org/10.2147/ndt.s64236
IF: 2.989
2014-01-01
Neuropsychiatric Disease and Treatment
Abstract:Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.
What problem does this paper attempt to address?